newsfilter
← Latest News
Business Wire·

Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026

VARIPURE findings reported 100% acute procedural success with the VARIPULSE Pro Platform, 0.4% primary adverse event rate and a mean ablation time of 17.9 minutesi Omny-IRE data showed 82.5% of patients treated with